期刊文献+

低剂量5-Fu长期持续静滴治疗晚期恶性肿瘤 被引量:2

Long Term Continuous Intravenous Drip Infusion of Low-Dose of 5-Fluorouracil for Advanced Malignant Tumors
原文传递
导出
摘要 目的观察低剂量5-氟尿嘧啶(5-Fu)长期持续静滴治疗常规含5-Fu类方案失败的晚期恶性肿瘤的近期疗效和毒副反应。方法 19例经传统的含5-Fu类方案化疗失败的晚期恶性肿瘤患者,给予5-Fu200mg/(m2.d)微量泵持续静脉滴注,治疗至疾病进展,每30d后以RECIST评价标准评价疗效,以NCI抗癌药物毒副反应0~Ⅳ级评价毒性反应。结果全组19例均可评价,其中完全缓解(CR)0例,部分缓解(PR)2例,稳定(SD)8例,进展(PD)9例,有效率(RR)10.5%,临床获益率(CR+PR+SD)52.6%。毒副反应主要是Ⅰ~Ⅱ级胃肠道反应及手足综合征。结论低剂量5-氟尿嘧啶长期持续静滴治疗常规含5-Fu类方案失败的晚期恶性肿瘤的近期疗效较好,毒副反应较低,值得进一步研究应用。 Objective To investigate the clinical outcome and toxicity of long term continuous infusion(CI)of low dose of 5-FU for the patients who were relapsed or resistant to short term continuous infusion 5-Fu or xeloda-based chemotherapy.Methods 19 patients who were relapsed or resistant to short term continuous infusion 5-Fu or xeloda-based chemotherapy were subjected to long term CI 200 mg/(m^2·d)5-FU through portable pumps until disease progression.After each 30-day course of the treatment,the efficacy and toxicity were evaluated by Response Evaluation Criteria in Solid Tumors(RECIST)and the NCI anticancer drug toxicity criteria,respectively.Results Among all the 19 evaluable cases,there were 0 complete remission(CR),2 partial remission(PR),8 stable disease(SD),and 9 progressive disease(PD).The response rate(RR=CR+PR)and the clinical benefit rate(CR+PR+SD)were therefore 10.5% and 52.6%,respectively.Toxicities were mainly grade Ⅰ-Ⅱ mucositis and hand-foot syndrome.Conclusion The long term protracted CI of low-dose 5-FU has a better effect on refractory or relapsed patients failed to 5-Fu or xeloda-based chemotherapy.
出处 《中华全科医学》 2010年第7期843-844,共2页 Chinese Journal of General Practice
关键词 低剂量5-氟尿嘧啶 持续静滴 难治或复发肿瘤 Low-dose of 5-FU Continuous intravenous drip infusion Refractory or relapsed tumors
  • 相关文献

参考文献12

  • 1朱益平,程静,郭祖峰,戴金珠.多西紫杉醇联合奥沙利铂、甲酰四氢叶酸/5-氟尿嘧啶治疗晚期胃癌疗效分析[J].实用全科医学,2008,6(5):449-450. 被引量:4
  • 2Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubiein and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial [ J ]. Onkologie, 2009,32 ( 8-9 ) : 468- 472. 被引量:1
  • 3Chang AY, Lopes G, Hsin KW, et al. Phase II trial of 5-fluorouracil/ leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma:a cancer therapeutics research group study [ J ]. Clin Colorectal Cancer, 2007,6 ( 9 ) : 646- 651. 被引量:1
  • 4Bae WK,Hwang JE,Shim HJ,et al. Phase II study of docetaxel,cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer [ J ]. Cancer Chemother Pharmaco1,2010,65 ( 3 ) :589-595. 被引量:1
  • 5Longley DB, Harkin DP, Johnston PG, et al. 5-fluorouracil: Mechanisms of action and clinical strategies[ JJ. Nat Rev Cancer,2003,3: 330-338. 被引量:1
  • 6Hoff PM, Ansari R, Batist G, ct al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic coloreetal cancer: results of a randomized phase 1H study[J]. J Clin Oncol,2001,19(8) :2282-2292. 被引量:1
  • 7Folkman J. Anti-angiogenesis : new concept for therapy of solid tumors [J]. Ann Surg,1972,175(3) :409-416. 被引量:1
  • 8Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice [ J ]. J Clin Invest,2000,105 (8) : 1045-1047. 被引量:1
  • 9Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels[J]. Ann Oncol, 2002,13 ( 1 ) : 73-80. 被引量:1
  • 10Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma[ J ]. Caneer,2003,98 ( 8 ) : 1643-1648. 被引量:1

二级参考文献4

共引文献3

同被引文献13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部